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Each  year,  200,000  more  women  die  from  breast  and  cervical  cancer  than  from  pregnancy  and  childbirth.
Over  50%  of  deaths  from  breast  cancer  and  88% of deaths  from  cervical  cancer  occur  in  less developed
regions,  where  gender  discrimination  and  extreme  poverty  severely  limit  a woman’s  choice  to  seek  care.
Health systems  in  low-  and  middle-income  countries  (LMIC)  are  overwhelmed  with  competing  priori-
ties,  while  providers  of  care  are  unprepared  to deal with  the  growing  epidemic  of cancer.  Women  with
cancer  face additional  burdens  as the need  to attend  to a  personal  health  crisis  is outweighed  by  primary
responsibilities  to  the  family.  Myths  about  cancer  and  taboos  about  women’s  bodies  in  more  conservative
societies  render  these  women  at signiﬁcant  risk  of being  abandoned  by their  husbands  and  ostracized  by
their  community.  However,  there  is  hope  for  hundreds  of  thousands  of  women  confronting  these chal-
lenges.  Innovative,  interdisciplinary  programs  are  being  piloted  in  lower  resource  settings  throughout
the  Americas,  Asia  and sub-Saharan  Africa.  Some  have  already  shown  great  promise  to  reduce  death  and
disability  from  breast  and  cervical  cancer,  while  strengthening  primary  care  and  health  systems  overall.
Breast  and  cervical  cancer  control  should  be viewed  as  a “best  buy”  investment  opportunity  to  reduce
health  expenditures.  Implementation  and  cost-effectiveness  research  can  inform  rational  cancer  policy
not only for  developing  countries,  but also for  high-income  countries  where  resources  are increasingly
strained.  Women  leaders  in the  health  and  education  sectors  can  play  a pivotal  role  in prioritizing  cancer
within the  framework  of  women’s  health  and  equity.
© 2013 The Author. Published by Elsevier Ltd. 
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Cancer is emerging as an under-recognized global threat to
uman development [1–3]. It is estimated that by 2030 there will
e 22.2 million new cases of cancer and 12.7 million cancer-related
eaths worldwide [3]. More than half of new cases and two-thirds
f cancer deaths will occur in low and middle-income countries
LMIC) where access to early, accurate diagnosis and quality care
re woefully lacking [4]. The growing cancer burden has espe-
ially harsh consequences for women due to gender discrimination,
tigma, and cultural taboos, along with well-founded fears of aban-
onment or even violence, all of which conspire to limit women’s
hoices to seek care even when it is available [5]. A woman who
evelops breast cancer in the USA or UK has an 85–90% chance of
urvival; in many low income counties, her odds of survival are as
ow as 10–25% [6–8]. As has been said of maternal deaths, the like-
ihood of surviving cancer should not depend on where a woman
ives. This (mis)fortune of geography is a poignant example of what
elicia Knaul of the Harvard Global Equity Initiative calls “an equity
mperative” [9].
In 2013, where are women’s cancers on the global health
genda? Let’s consider for a moment another pressing issue which
isproportionately affects women in LMIC, maternal mortality. Mil-
ennium Development Goal #5 sets speciﬁc targets and indicators
o improve maternal health [10]; philanthropic, governmental and
on-governmental organizations (NGOs) have contributed sub-
tantial funding toward this effort [10–12]. It is therefore puzzling
hat women’s cancers (indeed all cancers) are not speciﬁcally
ddressed by any of the MDGs, when 200,000 more women  die
ach year from breast and cervical cancer than from complications
ue to pregnancy and childbirth [13–15].
In 2008 there were an estimated 1.38 million new cases and
58,000 deaths from breast cancer [16]. GLOBOCAN consistently
anks breast cancer as the most common cancer in women in
ost countries, accounting for 23% of all new cases. Approximately
alf of new cases and close to 60% of deaths occur in low- and
iddle-income countries, where the incidence is rising rapidly
ith economic development [16,17]. Worldwide, cervical cancer
as the third most common cancer in 2008, with 85% of an esti-
ated 529,000 new cases and 88% of 275,000 deaths occurring
n developing countries [15,18]. Despite the remarkable progress
n reducing the cervical cancer burden where screening has been
idely available [19–21], organized cervical cancer screening pro-
rams have yet not been implemented in most LMIC. Consequently,
n 2008 the overall mortality: incidence ratio was only 52% [14],
nd 5-year age-adjusted standardized survival is still reported as
ow as 19.8 in Uganda [8]. Mortality from cervical cancer surpasses
reast cancer mortality in many regions within rural South Asia and
ub-Saharan Africa [14,15,8,22].
What of the social and economic impact of women’s cancers in
ow and middle-income countries? Can research conducted in LMIC
ontribute to innovative cancer policy for high-income countries,
here cancer resources are strained to the breaking point?
This paper will attempt to address these issues and show that:
. Reducing disability and death from breast and cervical cancer in
low- and middle-income countries is not only a moral impera-
tive, but also an investment opportunity that can save precious
resources, reducing strain on health systems everywhere.
. Avoidable suffering and death from breast and cervical cancer
is a human right’s issue. Women’s empowerment should frame
community-based interventions to make real and lasting impact.. Opportunities abound to work collaboratively across health dis-
ciplines to build capacity for the care and control of women’s
cancers. Evaluation of pilot programs along with social science
and implementation research should be conducted within LMIColicy 1 (2013) e35– e41
to inform rational cancer policy for developing countries as well
as high-income countries, where resources are severely strained.
4. Women  leaders should use their platforms to elevate the status
of women, reduce gender inequity, and place women’s cancers
where they belong on their public health agendas.
Box
Imagine you are a 38 year old woman  in rural Bangladesh. You
notice a large lump in your left breast, and it begins to grow. Three
months later you also notice a lump under your left arm. You are
married, have 4 children and live with your in-laws in their home.
Your priorities are clear: to feed and care for the family, tend the
home, and ensure there is enough money for school uniforms, pen-
cils and books. Your husband tends the small family farm, and you
all pray that the seasons will be favorable this year. As a duti-
ful mother, daughter-in-law, and wife, self-oriented considerations
rarely, if ever, enter your mind. The health and well-being of every-
one else should come ﬁrst. Besides, you have never met, or even
heard of anyone surviving a dreaded diagnosis of cancer. The very
word instils fear – fear of bringing shame upon your family, fear
of being cast-out from your community, and fear of an untimely
death. What choice do you have but to carry on, and hope that (god
willing) things will get better?
Women’s cancers in LMIC: an economic imperative
This rising burden of cancers in developing countries reﬂects
the epidemiological transition from infectious diseases to chronic,
non-communicable diseases (NCDs) [23]. As deaths from infec-
tious diseases decline and life expectancy increases with economic
development, there is a profound shift in the common NCD risk
factors including tobacco use, harmful consumption of alcohol,
adoption of a Westernized diet, and sedentary lifestyles [24].
Recently, Bray et al. [3] described the “cancer transition”:
changes in the patterns of speciﬁc cancers stratiﬁed by four tiers
of the Human Development Index (HDI), a combination of life
expectancy, education and GDP per capita. Their projections for
cancer trends to 2030 suggest that decreases in cancers caused by
infections (i.e. cervical cancer) will be offset by increases in cancers
associated with the common NCD risk factors. For breast cancer,
the rise in incidence is expected to be particularly rapid due the
concomitant shift in known reproductive risk factors (earlier age at
menarche, later age at ﬁrst birth, lower parity, and lower rates and
duration of breast feeding) [18].
Over the past four decades cervical cancer incidence and
mortality rates have fallen sharply, where population-based
screening became widely available [18–21]. Human development is
expected to bring rapid improvements in health systems such that
population-based cervical screening programs (and presumably
HPV vaccination) will soon be widely adopted [3]. This encourag-
ing prediction would, however, also have to assume high levels of
community acceptability and utilization across populations, many
of which include culturally conservative communities. Perhaps a
more realistic view is that for many lower-resource populations, it
will be many years to come before most of the women at risk will
be spared an untimely death from cervical cancer.
In the meantime, it will be of paramount importance help build
capacity for basic cancer services (for all common tumor sites)
including education and training, diagnostic pathology, surgery,
radiotherapy, chemotherapy, and palliative care. Later in this paper
we highlight examples of innovative projects to build capacity for
breast and cervical cancer services in LMIC.
Although premature death and disability from cancer has the
greatest economic impact from all causes of death worldwide, an
estimated 5% of global resources are spent in developing countries
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Table  1
Cervical cancer: estimated disability-adjusted life years (DALYs), years of life lost (YLLs) and years lived with disability (YLDs) rate/100,000.
Country Cervical cancer
DALYs YLLs YLDs
Number ASR(W) Number ASR(W) Number ASR(W)
India 2,386,943 466 2,177,432 428 209,510 37
Pakistan 243,560 393 225,905 369 17,655 24
Bangladesh 353,861 554 329,984 520 23,878 34
South  Asiaa 2,984,364 2,733,321 1317 251,043 95
Sub-Saharan Africa 1,559,853 641 1,459,778 607 100,075 34
Northern America 153,658 74 120,320 55 33,338 19
Western Europe 102,518 79 82,237 58 20,282 20
Less  developed regions 7,749,748 332 6,969,575 303 780,173 29
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aMore  developed regions 988,256 122 
Combined DALYs for India, Pakistan and Bangladesh: the 3 most populous South A
here 80% of the burden exists [25]. Even without direct medical
xpenditures, cancer costs an estimated 895 billion USD, or 1.5% of
he global GDP; approximately 20% higher than that for cardiovas-
ular disease [26]. The American Cancer Society Report, “The Global
conomic Cost of Cancer” summarizes death and disability from 17
ifferent cancers among 188 WHO  member states. They conclude
hat the years of life and productivity lost due to cancer “represent
he single largest drain on the global economy including HIV/AIDS
nd other infectious diseases”.
Cancers with the largest economic impact in low income
ountries include breast and cervical cancer. Tables 1 and 2
llustrate the magnitude of the problem in terms of estimated
isability-adjusted life-years for more developed and less devel-
ped countries [27,28]. In “closing the cancer divide: an equity
mperative” [9], Knaul et al. devote a chapter to the case for invest-
ng in cancer care and control. They explore macroeconomic cost
odels and potential cost-savings from treatment and prevention
ith particular emphasis on breast, cervical and colorectal can-
er, sites for which prevention or early detection make the largest
mpact on morbidity and mortality. Estimated losses are presented
n DALYs as well as Value of Statistical Life (VSL), and they predict
otential savings under different scenarios, with more- (49%) or
ess-conservative (36%) estimates of avoidable deaths. According
o their assessment for 2010, global investment in cancer care and
ontrol might have saved from $10 to $230 million in DALYs or $531
o almost $1 trillion in VSL. Of particular relevance to women, they
emonstrate that the cost savings of a “prevention/early detection
nd treatment approach” for breast and cervical cancer are actu-
lly greater than for a “treatment only approach” (Fig. 1) [9,29]. In
erms of cost-effectiveness, a recent analysis of screening and treat-
ent for breast, cervical and colorectal cancer in sub-Saharan Africa
nd Southeast Asia highlight speciﬁc interventions which are highly
ost-effective in both regions [30]. These include cervical screening
able 2
reast cancer: estimated disability-adjusted life years (DALYs), years of life lost (YLLs) an
Country Breast cancer
DALYs 
Number ASR(W) 
India 1,857,771 362 
Pakistan 373,557 598 
Bangladesh 341,670 502 
South  Asiaa 2,572,998 
Sub-Saharan Africa 1,233,103 479 
Northern America 1,451,377 579 
Western Europe 1,062,997 681 
Less  developed regions 9,593,905 387 
More  developed regions 5,533,146 574 
Combined DALYs for India, Pakistan and Bangladesh: the 3 most populous South Asian c818,706 96 169,549 26
ountries. GLOBOCAN 2008, IARC – 19.2.2013.
by VIA or Pap smears in combination with evidence-based treat-
ment: cost <$Int 2000 per DALY averted).
Women’s cancers and the cycle of poverty: what of “cancer’s
orphans”?
In North America and Europe, most women  with breast can-
cer are diagnosed after menopause, with half of all cases occurring
between ages 50 and 69. In USA, the median age at diagnosis is 61
[31]. In contrast, breast cancer in the developing world is largely a
disease of younger, premenopausal women [32,33]. In India, breast
cancer incidence peaks between ages 45 and 50 [34,35]. The median
age of diagnosis for cervical cancer is 48 in USA [36] and 38 in India
[range 21–67] [37]. The earlier age of breast cancer in developing
countries is likely related (at least in part) to the striking differences
in population structure; the median female age is 41.2, 29.1 and 25
in UK, Indonesia, and Malawi, respectively [38]. The age at which
cervical cancer is diagnosed is strongly correlated with age at ﬁrst
sexual activity.
What of children left behind when a mother dies of cancer? The
devastation of a mother’s death to HIV/AIDS is a well-described
tragedy for families and communities, particularly in sub-Saharan
Africa [39]. Given the young ages of onset, the high case-fatality
ratio, as well as the considerable costs of cancer treatment (virtu-
ally none of which may be covered by public or private insurance)
the social and economic burden imposed on families can be dev-
astating. In countries with extreme poverty, a mother’s death can
have catastrophic consequences on the children left behind. For
some of these orphans, their own  lives are often cut short after
their mother’s death, due to undernourishment and neglect.
In Bangladesh, a large cohort study led by the International Cen-
tre for Diarrhoeal Disease Research, Bangladesh (icddr,b) described
the effect of a parent’s death from any cause on childhood survival
d years lived with disability (YLDs) rate/100,000.
YLLs YLDs
Number ASR(W) Number ASR(W)
1,581,878 309 275,893 53
328,314 528 45,243 70
299,026 440 42,645 62
2,209,218 1277 363,781 185
1,091,788 427 141,315 53
906,161 360 545,216 219
673,544 419 389,453 261
7,836,794 321 1,757,111 66
3,733,196 383 1,799,950 192
ountries. GLOBOCAN 2008, IARC – 19.2.2013.
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o age ten [40]. They reported the cumulative probability of sur-
ival to age ten was 89% if the mother survived and only 24% if the
other died. Not surprisingly, the effect was greatest if the mother
ied during the neonatal period or within the ﬁrst year. However,
ven among children who survived the neonatal period, the proba-
ility of survival to age ten was only 38% if the mother died, versus
3% if the mother lived (log-rank test p < 0.0001). The same anal-
sis was applied for fathers’ deaths. In stark contrast, there was
o interaction between the death of a father and the cumulative
robability of the child’s survival.
In many rural populations, women of child-bearing years often
end to farming, while at least some child care duties are assumed
y other female relatives including older sisters and maternal
randmothers. In much of South Asia including Bangladesh, women
o not generally work the ﬁelds but remain at home as the main
rovider of care. Previous research in Matlab region [41] suggests
hat child-rearing is the sole responsibility of the mother. It is also
he cultural norm for newly married women in rural Bangladesh
o move to their husband’s family’s home. She is thus separated
rom biological relatives, often by great distances. Fathers typically
rovide economically to the household but do not actively partici-
ate in raising the children [40]. Particularly in rural areas, the costs
o families for travel to the nearest hospital, let alone radiation and
hemotherapy are catastrophic costs which few families can afford.
While this important study highlights the impact of maternal
eath far beyond the ﬁrst year of life, it also suggests potential
onger-term impacts of those children who do survive to adulthood.
iven the apparent risks of malnutrition and neglect, what might
e the implications for the child’s education and future income
otential?
 human rights imperative
Box: from [5]
“When I told my  husband I had breast cancer he said I don’t want
anything to do with you, you can go die”- 45-year old divorced,
homeless woman from Jessore, Bangladesh”.
“An herbal “quack” doctor told me  he has a patient with a breast
lump he wants to bring to me,  but it is impossible because the
woman’s husband will divorce her if he ﬁnds out. I will have to go
to her home to see her.” -Jessore nurse describing a conversation
with an herbal doctor in her village.
“Two years ago I noticed a lump. The homeopath prescribed a
paste that made my  skin burn like a spice and now I can’t touch
my  breast because it’s so painful. My  husband earns Taka 150 cancer divide [9].
[. . . US $2] per day . . . he wants me  to go see a good doctor,
but it will take time to save up for this . . . my  last visit to the
doctor cost Taka 3000 (∼US $43).” 28-year-old interviewee from
Rampal
30-year-old interviewee from Rampal
Bangladesh is a country of 160 million people with an estimated
$2000 USD GDP per capita [37]. Despite growing urbanization, the
majority of the population live in rural areas. Due  to poor road
conditions, frequent inclement weather and travel costs most peo-
ple have limited access to the publicly funded health care system.
Public hospitals are located in urban centers, are understaffed and
severely over-crowded. The only public national cancer hospital is
based in the capital Dhaka, a population estimated at 14 million,
and serves a small fraction of cancer patients in the city.
Our previous work in Khulna Division (population ∼15,000,000,
140 km east of Kolkata) revealed that the vast majority of women
who eventually came to the local hospital or to our rural breast
clinics had advanced breast cancer (87% stage III, 9% stage IV) [5]. It
is important to note that “Stage III” understates the magnitude of
the problem – many women  have clearly inoperable disease with
skin ulceration, nipple retraction, as well as bleeding or fungating
masses. Many have palpable ﬁxed, matted axillary lymph nodes and
some present with obvious advanced brachial plexopathy. Access
to palliative radiation would thus provide tremendous relief for
patients and families. In the public hospital in Khulna City (pop
∼1 million), the only two  staff oncologists are primarily trained in
radiation medicine; however the closest radiation facility is 140 km
away, in a different division (Barisal). Travel is difﬁcult and takes
the better part of a day. Overcrowding and long wait lists make
treatment beyond the reach of most patients.
Delayed presentation of breast cancer is common throughout
the developing world, and some of this is attributed to ﬁrst seeing
a traditional healer. With limited access to proper care as well as
limited knowledge about cancer, many women throughout rural
Asia and Africa ﬁrst seek care from a “homeopath”, an “herbal doc-
tor” or other traditional healer which the patients themselves often
refer to as “quacks” [42–44].
In Khulna City, we asked the women  who ultimately presented
with advanced breast cancer if they knew they had had a seri-
ous breast problem (growing lump, skin or nipple changes) and
if so, for how long. Contrary to what some advocacy groups in the
West assume is a simple matter of “awareness”, the majority of
women we interviewed knew well that they had a serious, even
life-threatening breast issue. Yet many waited for months, even
years before seeking proper care. We  conducted semi-structured
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nterviews and focus groups to explore this issue. Some women
ited logistical and ﬁnancial considerations, many had seen a
homeopath” ﬁrst, and most believed that cancer could not be effec-
ively treated, let alone cured. Perhaps most concerning was  the
umber of women who also described fears of being abandoned
y their husbands, ostracized by their communities or even threat-
ned with violence (Heather Story, personal communication). Some
imply stated that they had “no choice”. As Fathalla states in her
ook about human rights and motherhood, “Women are not dying
ecause of untreatable diseases. They are dying because societies
ave yet to make the decision that their lives are worth saving”
45].
What of the belief that cancer is a death sentence? If you had
ever met, let alone heard about a cancer survivor, why would
ou think otherwise? Rational cancer policy must consider these
ealities and should include a balance of evidenced-based, locally
nformed and culturally tailored approaches to health promotion in
oncert with improved access to affordable care, in order to change
his grave situation for women everywhere. Choices to seek care
lso depend very heavily on the way these women view themselves,
heir status, and multiple roles as home-maker, child care-provider,
utiful wife and daughter-in-law. Research in different regions of
outh Asia and among SA immigrants to high-income countries
ighlights the same issues. Women  from newcomer and immigrant
opulations from South Asia tend to have lower rates of cancer
creening, even in countries with publically funded programs and
niversal health coverage [46,47].
Health inequity has recently become a subject of interest to legal
nd human rights groups, including Amnesty International [48]. In
ovember 2012, a report on access to cervical cancer screening and
reatment in Southern Africa was published by the Southern African
itigation Center (SALC), funded by the Ford Foundation and the
pen Society Initiative for Southern Africa [49]. A Lancet editorial
50] “The right to cervical cancer services in southern Africa” sum-
arizes their conclusions, “. . .failure to provide access to cervical
ancer services results in the violation of fundamental rights and
ecommends that southern African countries develop comprehen-
ive national policies on cervical cancer management”.
 research and evidence imperative
There are many untapped opportunities to reduce death and dis-
bility from breast and cervical cancer in LMIC without negatively
mpacting other key health and development priorities. Creative
pproaches to women’s cancer care and control are being tested
nd evaluated in a many different settings. Innovations include
nstitutional collaboration for off-site expert medical consulta-
ion, task shifting, along with creative use of existing technology:
elemedicine, e-health and “mHealth” – using mobile phones and
pplications to facilitate medical practice and public health inter-
entions.
nstitutional collaborations to inform best practices
The Breast Heath Global Initiative (BHGI) was  founded in 2002
to develop, implement and study evidence-based economically
easible, and culturally appropriate guidelines for international
reast health and cancer control in LMIC” [51]. Co-sponsored by
he Fred Hutchinson Cancer Research Center and Susan G. Komen
or the Cure, the BGHI pioneered the development of resource-
ppropriate guidelines for breast cancer care [52,53]. The most
ecent meeting, October 2012, was hosted by the UN International
tomic Energy Agency (IAEA) Program of Action for Cancer Therapy
PACT) in Vienna. The theme was supportive care and quality of life,
nd included 129 participants from 41 countries. Guidelines are in
evelopment (Dr B.O. Anderson, Fred Hutchinson Cancer Research
enter).licy 1 (2013) e35– e41 e39
In Peru, innovative programs for education, training and early
detection for breast and cervical cancer are being implemented
and evaluated through partnerships with the Peruvian Ministry of
Health, Pan American Health Organization (PAHO), the BHGI and
PATH. PATH is an international non-proﬁt organization with a focus
on innovation and collaboration to make impacts on AIDS, TB and
malaria as well as health equity for women, and access to vaccines
for women and children. Cervical cancer screening is performed
by trained mid-wives and primary care doctors, who  use a “screen
and treat” approach with VIA (visual inspection with acetic acid)
and cryotherapy [54].
In 2012 the Butaro Cancer Center of Excellence opened in Butaro
Hospital, northern Rwanda [55]. The ﬁrst such center to bring
comprehensive cancer care to rural East Africa, this achievement
was made possible by collaboration between the Government of
Rwanda Ministry of Health, Partners in Health (PIH), the Jeff Gor-
don Children’s Foundation, the Dana Farber/Brigham and Women’s
Cancer Center. With only two  trained oncologists in Rwanda the
Butaro center is building upon knowledge gained from the pre-
vious work of PIH, on expanding access to HIV and TB care. A
variety of approaches are being tested to build a comprehensive
and equitable system of cancer services along the entire spectrum
of cancer control and care. These include: task-shifting, off-site
pathology services, telemedicine consultation for clinical decision-
making with oncologists abroad as well as social services to support
the patients and families. Te Dana-Farber/Brigham and Women’s
Cancer Center along with other partners are providing training for
Rwandan staff for the safe administration of chemotherapy, and to
provide a sustainable system of education for the future. As part
of the Rwandan National Strategic Plan for the Prevention, Control,
and Management of Cervical Lesions and Cancer, Rwanda’s MOH
was also the ﬁrst in Africa to pilot HPV vaccination [56]; this pro-
gram also provides cervical screening and treatment for women
aged 35–45.
In August 2012, the WHO  in collaboration with the International
Agency for Research on Cancer (IARC) and the African Population
and Health Research Center (APHRC) published their report, “Pre-
vention of cervical cancer through screening using visual inspection
with acetic acid (VIA) and treatment with cryotherapy. A demon-
stration project in six African countries: Malawi, Madagascar,
Nigeria, Uganda, the United Republic of Tanzania, and Zambia” [57].
Training took place at the Department of Obstetrics and Gyne-
cology, University of Zimbabwe, Harare. Technical support was
provided for data management by the APHRC and IARC. Between
September 2005 and May  2009, nearly 20,000 women aged 30–50
were screened with VIA, 10.1% of which were VIA positive. Almost
90% of VIA-positive cases were eligible for cryotherapy. About 63%
received cryotherapy within 1 week of their screen, and the single-
visit approach was successful for 39.1%. The report highlights
successes and limitations, both of which inform their policy recom-
mendations, including: that each MOH  develop, update and review
their strategies for cervical cancer control based on national guide-
lines and WHO  standards; that implementation should include
health education along with adequate funding at all levels through
to district healthcare facilities; and that the programs should be
linked to sexual and reproductive health as well as other NCD pre-
vention and care.
Research partnerships for “integrated innovation”
Building from the Bill & Melinda Gates model, Grand Challenges
Canada [58] offers grants through its “Rising Stars in Global Health”
program for projects led by researchers based in LMIC (or in part-
nership with a Canadian researcher) to innovate for control of
NCDs including cancer. Proposals must be aligned with “Integrated
Innovation”, a balance of scientiﬁc/technical, social and business
innovation to maximize community impact and sustainability [59].
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ne such project currently underway is “the Kilimanjaro Cervical
creening Project” in which health workers perform screening by
isual inspection with acetic acid (VIA) and send images with their
obile phones “cervicography” for conﬁdential, prompt expert
onsultation [60]. Another study funded by GCC is our randomized
ontrolled “mHealth” trial for breast cancer in rural Bangladesh.
ur previous feasibility pilot demonstrated surprisingly high rates
f community acceptance, which we attributed largely to a long-
tanding trusting relationship of our local partner NGO, Amader
ram (“our village” in Bengali). In the current study we trained
0 community health workers and three female supervisors to use
mart phones loaded with our special apps to interview, educate,
xamine and refer women with suspected breast cancer to come
or further assessment. Over a four-month period the CHWs con-
ucted 20,000 interviews with women in their village homes. Data
nalysis is underway.
everaging resources: the end of silos?
Opportunities also exist to build bridges between traditionally
eparate domains, such as infectious diseases, maternal health, and
on-communicable, chronic diseases. While up to 26% of all cancers
n LMIC are related to infectious agents [61], and in some regions
IV and TB are becoming chronic diseases, traditional health “silos”
ppear outdated. Resources including ﬁnancial and human capital,
s well as community trust – an under-recognized but essential fac-
or in successful public health interventions – should be leveraged
o increase control and care for women’s cancers, while facilitating
mprovements to primary and reproductive care.
In September 2011, Pink Ribbon-Red Ribbon was launched by
he American organization PEPFAR (Presidents Emergency Plan for
IDS Relief) and includes non-proﬁt agencies such as Susan G.
omen for the Cure, the joint United Nations Program on HIV/AIDS
UNAIDS), as well as corporate donors (Merck, Becton-Dickinson,
ristol-Myers Squibb, GlaxoSmithKline and IBM) [62]. The pro-
ram, which combines HIV/AIDS care with breast health education
nd cervical cancer prevention and screening, is a salient example
f the “diagonal approach to health system strengthening” to build
apacity for cancer care and control [9]. With an initial commit-
ent of 75 million USD, there are now 250 participating sites in
1 countries. According to the PRRR, “Pink Ribbon Red Ribbon is
round breaking . . . links HIV and maternal and child health pri-
rities with non-communicable disease priorities; creatively com-
ines public and private resources; and signals growing consensus
hat concerted action must be taken to address cervical and breast
ancer in low-income countries . . . PRRR’s public–private model
ay  serve as a useful template for future health initiatives” [63].
onclusion and future directions
Morbidity and mortality from women’s cancers are shamefully
igh. Affordable access to early detection and proper treatment
or breast and cervical cancer, which disproportionally affect the
orld’s most disadvantaged women, should be a human rights as
ell as an economic priority. Collaboration between institutions in
igh- middle- and low-income countries will facilitate education
nd training for cancer control and care, while building research
apacity to inform best clinical practices relevant to all women  at
isk. Innovations to optimize human and technical capital should
e funded with particular incentives for junior researchers in LMIC.
On a cautionary note regarding pilot studies, there would appear
o be an “embarrassment of riches”; however transitioning to scale
s quite another matter. A recent opinion by Sam Loewenberg in
he New York Times, “Learning from Failure” [64], highlights the
ritical importance of not only recognizing when a global health
roject fails to achieve intended impact, but also of publishing
[
[olicy 1 (2013) e35– e41
and discussing negative results. The author concludes: “While aid
organizations must be accountable for outcomes that pressure for
positive results should not be an encouragement to skimp on the
truth. Making a difference in the world is hard, often messy work.
Pretending otherwise is no help at all.” The same might be sug-
gested for exporting programs to different populations, without
essential and extensive knowledge of the local environment, socio-
cultural as well as political contexts. Pilot studies in general, and for
women’s cancers in particular will have a greater chance of success-
ful scale-up if there is direct and early community involvement, as
well as commitment from national, regional and local government
agencies.
Women’s empowerment can be the basis for and the conse-
quence of effective breast and cervical cancer control. Many low-
and middle-income countries currently have elected women lead-
ers, and an increasing number have women professors in medical
schools and teaching hospitals. While having women in power is
no guarantee that a nation will reduce the gender and health equity
gap (so long as partisan politics, nepotism and corruption prevail) it
can provide an opportunity for positive change [65]. Women  with
senior roles in the health and education sectors should be encour-
aged to use their platform to elevate the status of women’s cancers
as part of the women’s health and equity agenda.
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